Professional Documents
Culture Documents
MEDICA 2019 Bioneer Corp. Paper Medcom2019.2624390 Magw5HQHTHyg2KdBHRQUKw
MEDICA 2019 Bioneer Corp. Paper Medcom2019.2624390 Magw5HQHTHyg2KdBHRQUKw
MEDICA 2019 Bioneer Corp. Paper Medcom2019.2624390 Magw5HQHTHyg2KdBHRQUKw
a Healthier Future
for Humanity
with BIONEER’s MDx
This material is prepared for the purpose of understanding BIONEER and its main business areas. Therefore, BIONEER is not responsible for investment decisions
etc. made based on this material. Also, it is prohibited to use, post and/or distribute part or all of this material without the expressed consent of BIONEER.
Copyright 2018, Bioneer Corporation. All rights reserved.
Features of BIONEER’s MDx
▌ Who is BIONEER?
Established
1992
1 Cooperation
1st Bio-venture with our partners Various MDx products
in Korea in approx. countries using own technologies
30
Innovation•Value•Discovery l BIONEER 2
Features of BIONEER’s MDx
▌ BIONEER’s MDx
In-house
Various
MDx Raw
Diagnostic
System Material
Kits
Production
Innovation•Value•Discovery l BIONEER 3
Features of BIONEER’s MDx
▌ BIONEER’s MDx
Raw material
Raw MDx MDx
material system kits MDx system
MDx Kits
Innovation•Value•Discovery l BIONEER 4
Features of BIONEER’s MDx
Innovation•Value•Discovery l BIONEER 5
Features of BIONEER’s MDx
BIONEER makes
global business
by cooperating
with many of
business partners!
Innovation•Value•Discovery l BIONEER 6
Features of BIONEER’s MDx
Innovation•Value•Discovery l BIONEER 7
Features of BIONEER’s MDx
SARS
SARS Diagnostic
Solution :
Swine Flu (H1N1)
Ebola Virus
Diagnostic Kit : ZIKV Zika Multiplex
Diagnostic Kit : Diagnostic Kit
ABADIS development
about 2 million : 1st multiplex kit
Mobile PCR Lab with Nigeria
cases were tested on WHO EUAL
in China Government
2003 2009 2014 2016
~2008 2009 2010 2011 2013 2014 2015 2016 2018 2019~
▪ ExiPrep™ 48Dx
Innovation•Value•Discovery l BIONEER 8
Features of BIONEER’s MDx
▌ Key Patents
Reagents and Kits (total 60)
No Application no. Patent no. Title Registered Pending
1 10-1999-004361 KR 0292883 Hot start PCR Mixture Comprising Pyrophosphate and Pyrophosphatase KR
2 10-2007-109055 KR 1098764 Dried Composition for hot-start PCR with Long-Term Stability KR, US, BR, IN, CN
KR(3), US, EP(GB, FR,
3 10-2011-0011639 KR 1818126 Reverse transcriptase having improved thermostability
DE), JP, CN
Compositions for hot start reverse transcription reaction or hot start reverse transcription EP(GB, DE, FR, CH),
4 10-2013-0025119 KR, US, CN, CA, IN, BR
polymerase chain reaction JP, AU, RU
5 10-2013-0091821 KR 1717953 New azo compound, use thereof, and process for preparing of the same JP EP, US, CN
Universal automatic apparatus for real time monitoring products of nucleic acid US, EP, CA, IN, BR, ,
3 10-2010-0021532 KR 1423936 KR, RU, JP, AU, ID
amplification reaction and method thereof TH, TR, CL
4 10-2010-0105630 KR 1420094 Automatic Real-time PCR system for the various analysis of biological sample KR, US, JP, CN, RU EP, IN
Innovation•Value•Discovery l BIONEER 9
Features of BIONEER’s MDx
Through-put
Max. No. of test / a day Hands on time Hands on time
Configuration Extraction PCR Analysis
(9-hour workday) (for Extraction) (for PCR)
ExiStation™
48 tests 15min 1hr 30min 15min 1hr 20min
(with 1 Exiprep™ 16 Dx)
ExiStation™
96 tests 30min 1hr 30min 15min 1hr 20min
(with 2 Exiprep™ 16 Dx)
ExiStation™
144 tests 45min 1hr 30min 15min 1hr 20min
(with 3 Exiprep™ 16 Dx)
ExiStation™ 48A 192 tests 5min 1hr 20min* 15min 1hr 20min
Innovation•Value•Discovery l BIONEER 10
Features of BIONEER’s MDx
▪ Pipetting free
: Use primary tube directly
: decapping/capping of sample tube and
sample transfer motions are all automated.
Innovation•Value•Discovery l BIONEER 11
Features of BIONEER’s MDx
Exicycler™ 96
Innovation•Value•Discovery l BIONEER 12
Features of BIONEER’s MDx
Features
• “Sample-in, Data-out” system
: Automatic process from sample preparation to Real-Time PCR
: No pre-treatment before sample preparation
• Outstanding Speed
: All process complete within 30min
Sample injection
: Hands-on time is < 1min to cartridge
• Various applications
: AMR (Anti-Microbial Resistance)
: TB-MDR & XDR (Extended Drug Resistance)
: HIV-1 / HBV / HCV viral load PCR reaction
20 min
: STI (Sexually Transmitted infections)
: Zika etc.
IRON-qPCR™ Workflow
Innovation•Value•Discovery l BIONEER 13
Various diagnostic kits
Innovation•Value•Discovery l BIONEER 14
Features of BIONEER’s MDx
Features
• CE List A approved HIV-1 VL test kit
• Quantification of HIV-1 viral load
• Specimens : EDTA-plasma
• Target & Analytical sensitivity
› Sensitive detection of various subtype of HIV-1 (group M, N and O)
› The LoD is 33.1 IU/ml (Subtype B)
› The LoQ is 50 IU/ml
The Result of Clinical Comparison with cobas® 6800 at Cerba Center in Paris
Innovation•Value•Discovery l BIONEER 15
Features of BIONEER’s MDx
Features
• Quantification of HBV viral load
• Specimens : Serum, EDTA-plasma
• Target & Analytical sensitivity
› Sensitive detection of various genotype of HBV (genotype A to G)
› The LoD is 6.02 IU/ml (Genotype A2)
› The LoQ is 15 IU/ml
The Result of Clinical Comparison with cobas® 6800 at Cerba Center in Paris
Innovation•Value•Discovery l BIONEER 16
Features of BIONEER’s MDx
Features
• Quantification of HCV viral load
• Specimens :Serum, EDTA-plasma
• Target & Analytical sensitivity
› Sensitive detection of various genotype of HCV (genotype 1 to 6)
› The LoD is 10.7 IU/ml (genotype 1a)
› The LoQ is 15 IU/ml
The Result of Clinical Comparison with cobas® 6800 at Cerba Center in Paris
Innovation•Value•Discovery l BIONEER 17
Various diagnostic kits
MTB detected
1st Drug
RIF Rifampicin
AccuPower® TB&MDR kit
TB&INH Isoniazid
EmbB Ethambutol
XDRB
rpsL Streptomycin 2nd Drug
AccuPower® XDR-TB kit
gyrA Fluoroquinolones
XDRA
rrs Second line injectable agents
(Amikacin, Capreomycin, Kanamycin)
Innovation•Value•Discovery l BIONEER 18
Various diagnostic kits
• Target
› MTB : IS6110 rpoB:
505Leu 526Asn
MTB:
IS6110
509Arg 526Leu
› RIF : rpoB (10 mutant sites, 29 mutations) 509Ile 526Gln katG:
511Pro 526Pro 315Ile
› INH : inhA, katG (3 mutant sites, 7 mutations) 513Lys 526Arg 315Asn
513Pro 526Gly 315Thr
513Leu 530Leu (ACC)
• Analytical Sensitivity 516Tyr 531Leu 315Thr
516Asn 531Ala (ACA)
› MTB : 21.88 copies/test 516Pro
516Gly
531Gln
531Trp inhA:
516Val
› RIF : 3.98 copies/test 518Ser
533Pro
533Thr
-15T
-8A
526Tyr 533Leu -8C
› INH : 179.8 copies/test 526Asp
Innovation•Value•Discovery l BIONEER 19
Various diagnostic kits
• Target
rpsL
› Fluoroquionolone : gyrA XDRA1 XDRA2
A128G
Innovation•Value•Discovery l BIONEER 20
Various diagnostic kits
Innovation•Value•Discovery l BIONEER 21
Various diagnostic kits
CT 100% (95%C.I 94.8-100) 100% (95%C.I 75.3-100) TV 100% (95%C.I 90.5-100) 100% (95%C.I 76.8-100) UP 100% (95%C.I 98.1-100) 99.5% (95%C.I 97.2-99.9)
NG 100% (95%C.I 93.6-100) 100% (95%C.I 76.8-100) MH 100% (95%C.I 92.7-100) 100% (95%C.I 75.29-100) CA 100% (95%C.I 96.9-100) 99.3% (95%C.I 97.4-99.9)
UU 100% (95%C.I 92.7-100) 100% (95%C.I 76.8-100) HSV1 100% (95%C.I 88.4-100) 100% (95%C.I 75.3-100) TP 100% (95%C.I 74.1-100) 99.7% (95%C.I 98.4-100)
MG 100% (95%C.I 93.5-100) 100% (95%C.I 976.8-100) HSV2 100% (95%C.I 92.5-100) 87.5% (95%C.I 61.65-98.5) GV 100% (95%C.I 98.3-100) 100% (95%C.I 97.8-100)
Innovation•Value•Discovery l BIONEER 22
Summary
Innovation•Value•Discovery l BIONEER 23
Thank you
www.bioneer.com